3rd University Clinic of Internal Medicine, Aristotle University of Thessaloniki, Greece
Received date: December 12, 2016; Accepted date: January 23, 2017; Published date: February 13, 2017
Citation: Siomos K, Papadakis E, Tsamardinos I, Kerkentzes K, Koygioylis M, et al. (2017) Prothrombotic and Endothelial Inflammatory Markers in Greek Patients with Type 2 Diabetes Compared to Non-Diabetics. Endocrinol Metab Syndr 6: 259. doi:10.4172/2161-1017.1000259`
Copyright: © 2017 Siomos K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Visit for more related articles at Endocrinology & Metabolic Syndrome
Objective: To evaluate specific factors of coagulation and endothelial inflammatory markers namely, thrombomodulin, soluble receptor of the protein C (sEPCR), factor VIII, plasminogen activator inhibitor 1, Von Willebrandt factor, fibrinogen, fibrinogen dimers (d-dimers), high sensitivity C-reactive protein and homocysteine in a subset of Greek subjects with and without Type 2 (T2) Diabetes. Design: 84 subjects, of which 44 patients with T2 diabetes, were included in the randomized comparative prospective cross sectional study. The subjects were split into a Τ2 diabetics group and a group of healthy controls of similar age, anthropometric profiles and similar gender distribution.
Results: A total of 47 variables and biomarkers together with indicators for metabolic profiles, clinical history, as well as detailed anthropometric profiles and traditional risk factors, were evaluated. Dipeptidyl peptidase-4 (DPP4), Insulin, use of Sulfonylurea, high HBA1c and glucose levels, were clearly statistically differentiated in the two groups, while no other biomarkers including the new potential indicators were found to be different. High values of thrombomodulin and homocysteine were correlated with a rise in creatinine and thus seem to affect renal function in the diabetic patients group while in the non-diabetics group the correlations are different with sEPCR having a relative strong negative correlation in renal function as measured with The Modification of Diet in Renal Disease, in agreement with the latest international findings.
Conclusions: The presence of T2 diabetes in conjunction with age clearly correlates with problems in renal function, thrombomodulin and homocysteine could serve as indicators for renal damage in diabetics but not in healthy individuals. sEPCR on the other hand could be a potential generic indicator for renal damage. Thrombomodulin and sEPCR as prothombotic agents, did not show any indication that they can be utilised as markers for the prevention and/or treatment of thrombotic complications in diabetic patients.
Diabetes; Thrombomodulin; sEPCR; Prothrombotic markers; Endothelial inflammation
Τ2 diabetes is a high prevalence syndrome characterized by high blood glucose levels due to inability/failure of insulin production by the body, limited action of the produced insulin, or a combination of both situations. (1) Dealing with diabetes is a daily challenge for the clinician. Despite tremendous achievements in the diagnosis, monitoring and treatment of diabetes, diabetic patients continue to experience cardiovascular complications that result in death at an elevated rate.
The prevalence in 2015 reached 59.8 million just in Europe alone, representing 9.1% of the adult population. Today the population of patients with diabetes worldwide is estimated at 387 million, a figure that far exceeds initial forecasts. In Greece the disease prevalence in 2015 was 7.5%.  Prevalence of medication-prescribed diabetes was 7.0% going up to 8.2% in adults, and 30.3% in those more than 75 years old in the Greek population based on real-world data from the nation-wide prescription database.  The major complication of diabetes is microangiopathy (retinopathy and nephropathy), macroangiopathy (coronary heart disease, strokes, peripheral vascular disease) and neuropathy [3,4]. In Greece, diabetes is the leading cause of vision loss, end stage renal failure and the primary cause of amputation and erectile dysfunction with a very high cost for the patient [5,6]. Diabetes unfortunately coexists with other serious conditions such as dyslipidemia, hypertension and obesity increasing the risk of complications with the modern lifestyle further exacerbating its morbidity .
The study of blood coagulation is a promising scientific area of research with many new discoveries. A question that arises is what happens to patients with Τ2 diabetes at the blood coagulation level and how the markers of inflammation and pro - coagulant factors change, eventually leading to thrombotic events. The application of new knowledge in blood coagulation in diabetes could be of significantly help in the prevention and treatment of thrombotic complications in diabetic patients [7-9]. Blood coagulation has been previously studied, as have been proinflammatory agents in Τ2 diabetic patients, but these studies have not included the recently discovered agents such as thrombomodulin and the Soluble Endothelian Receptor Protein C (sEPCR) [10,11]. Thrombomodulin, an endothelian transmembrane protein, heavily involved the regulation of inflammation though binding to thrombin, acts as an anticoagulant and is a vital cofactor for thrombin-mediated activation of protein C, which is promoted further by the endothelial cell protein C receptor (EPCR), its soluble form circulates in plasma and inhibits activated protein C anticoagulant activity [12,13].
In this study we focused on specific factors of coagulation and endothelial inflammation markers. Specifically, thrombomodulin, [11,14] the soluble receptor of the protein C  (sEPCR), factor VIII,  plasminogen activator inhibitor 1 (PAI 1) , von Willebrandt factor (VWF), [18-20] fibrinogen, fibrinogen dimers (-dimers), high sensitivity C-reactive protein (hsCRP)  and homocysteine  in a subset of Greek subjects.
This is the first study to examine thrombomodulin and sEPCR together wih the other indicators of thrombosis and endothelial inflammation (PAI 1, D-dimers, VWF, VIII, FIB) in a population of patients with diabetes in the Greek area. There is very little known, even at international level, for sEPCR and thrombomodulin in small scale studies [10, 11,14,15].
A randomized comparative prospective cross sectional observational case -control study was conducted at the 3rd Department of Internal Medicine of Aristotle University of Thessaloniki in "Papageorgiou" General Hospital of Thessaloniki in October 2012. Recruitment was random with all subjects that came to the Department during 1st to the 31st of October, 200 in total, were asked to participate in the study. Consenting subjects were split into two groups, a Type 2 diabetics group (Group 1) and a non-Diabetics control group (Group 2). Subjects with a history of cancer, family history of thrombophilia, use of oral contraceptives, history of miscarriages, a recent history of coronary heart disease and stroke, end stage renal disease were excluded from the study, Figure 1 has the study inclusion exclusion flow chart. The final study population comprised 84 subjects that gave their informed consent and did not meet the exclusion criteria. Group 1 comprises 44 subjects with Type 2 Diabetes, 24 male and 20 female, with an average age of 61, while the Control group (Group 2 ) included 40 subjects without type 2 diabetes, 19 male and 21 female with an average age of 59. All subjects underwent a complete physical examination, height, weight (SECA 754, Germany), and waist circumference measurements to calculate the BMI along with blood pressure (mm Hg) (SK Welch Allyn). A complete personal and family medical history was taken, including information such as the duration and type of diabetes, concomitant disease, medication, smoking, alcohol consumption. Blood samples from all participants underwent comprehensive biochemical testing in order to have a metabolic profile for each subject, comprising measurements of levels of glucose(mg/dl), HDL(mg/dl), LDL (mg/dl), triglycerides(mg/dl), cholesterol(mg/dl) (Auto analyzer-Architect 8000 c, Abbott USA), and proinflammatory factors hs-CRP(mg/L) and fibrinogen(g/L) (Dade® Fibrinogen Determination Kit, Dade Behring GMbH, Germany), glycosylated hemoglobin (HbA 1c/HbA2, mmol/mol ) (HPLC Menarini-Akray HA 8160 Japan), urea (mg/dl), creatinine (mg/dl), K (mmol/L), Na (mmol/L) (Autoanalyzer -Architect 8000 c, Abbott USA), for the assessment of renal function and calculation of the glomerular filtration rate (GFR - MDRD) as well as CBC and full urine analysis (XT-4000i ™ Automated Hematology Analyzer, Sysmex Japan). Furthermore, assessment of thrombotic agents PAI 1(ng/ml), D-dimers (μg/ml), Thrombomodulin(ng/ml), sEPCR (ng/ml) VWF (VWF: Ag %), VIII(VII: Ag %), were performed by ELISΑ (using respective Asserachrom enzyme monoclonal Immunoassay kits, Stago France, BCS XP System Siemens Germany) with additional testing for Total LHomocycteine( μmol/l) also performed (FPIA AxSYM, Abbott USA). All blood and biochemical tests were conducted at the Hematology Laboratory-Haemostasis Unit of the same hospital.
Permutation-based Monte-Carlo permutation test statistical tests  were used in most cases with N=2000 permutations in each case. All variables with discrete values were treated as qualitative variables. The independence test used was the permutation-based Pearson's χ2 test. For continuous variables permutation-based T-tests (independent samples, non-directional), non-directional Wilcoxon rank sum tests and two-sample Kolmogorov-Smirnov (non-parametric) tests were conducted where appropriate with the above mentioned number of permutations. All analyses were 2-sided, Shapiro-Wilk test was used to assess for normality of continuous variables and a FDR (corrected P value) of ≤ 0.05 was considered statistically significant. A multivariate Monte-Carlo permutation-based version of Hoteling’s test with independent samples assuming unequal covariance was performed between thrombomodulin, Fibrinogen, VIII, VWF, PAI, and sEPCR and disease status. Power analysis has been performed with the G*Power tool version 3.1.3 . For the continuous tests the effect sizes d of 0.2, 0.5, 0.8 are considered small, medium, and large. For the χ2 test the effect size w of 0.1, 0.3, and 0.5 are considered small, medium, and large respectively. All statistical analysis, was done using mat lab, Release 2011α, The MathWorks, Inc., Natick, Massachusetts, United States, G*Power,  v 3.1.3, R, v 3.0.2 (R packages pspearman, v 0.2-5, mass, v7.3-30,nortest, v1.0-2). Plots and graphs were created using R Packages, lattice v0.20-27, plotrix, v3.5-5 and ggplot2, v0.9.3.1 .
A total number of 47 variables and biomarkers together with indicators for metabolic and clinical history profiles, as well as detailed anthropometric profiles and traditional risk factors, were evaluated and are listed in Table 1. The multivariate test, assuming multivariate normality of the distribution did not result in more discoveries, (pvalue= 0.1530).
|Mean||95% CI||Mean||95% CI||Mean||95% CI|
|Disease Duration (Years)||11.295||9.562||5.940||8.907|
|Waist circumf (cm)||106.273||102.9-109.65||100.125||95.42-104.83||103.345||100.48-106.21|
|Systolic pressure (mmHg)||139.818||134.19-145.44||129.675||126.05-133.30||134.988||131.47-138.51|
|Diastolic pressure (mmHg)||78.841||75.93-81.75||82.000||78.80-85.20||80.345||78.21-82.48|
|Pulse Rate (b/min)||74.386||70.78-78.00||72.675||70.23-75.12||73.571||71.39-75.75|
Table 1: Descriptive statistics for the diabetic, non-diabetic groups and total population.
The initial statistical comparison focused on the descriptive statistics (Tables 1 and 2) of all variables between the two groups. Both groups were found to have similar age distribution and gender ratio and similar anthropometric profiles (Tables 1 and 2).
|Group||Abs. Freq.||%||Abs. Freq.||%||Abs. Freq.||%|
Table 2: Qualitative statistics for the diabetic and non-diabetic groups.
It is evident from the data of (Table 3), that there are no differences in the two groups in terms of age, gender, smoking status, BMI, and non-diabetic medication and only showed statistical difference with an adjusted p-value (FDR)< 0.05 in the variables DPP4, Insulin, Sulfonylurea, HBA1c and glucose that are indeed only present in the diabetic group, as expected . All other variable comparisons showed no significant statistical difference between the two groups.
|Variable||(T-test/χ2)||(RS/Perm)||K-S||FDR adjusted p|
|Prescribed omega lipids||0.234604||0.3015||NaN||0.51255|
Table 3: Statistical analysis of all the variables.
Correlations between variables in the diabetics group
Thrombomodulin has a very strong positive correlation (r=0.730 p. adj< 0.000001) with creatinine in the diabetics group. Equally strong is homocysteine’s correlation with creatinine with a positive correlation (r=0.670, p. adj< 0.00001). High values of thrombomodulin and homocysteine are correlated with a rise in creatinine and thus affect renal function of the diabetic patients as seen in (Figure 1A). In the non-diabetics group the correlations are different. sEPCR is shown to have a relative strong negative correlation (r=-0.449 p. adj=0.0417) in renal function as measured with MDRD shown in (Figure 1B).
Figure 1: A) Correlations in the diabetics group for Thrombomodulin and Creatinine (r=0.730 p. adj< 0.000001) and Homocysteine and Creatinine (r=0.670, p.adj< 0.00001). B) Correlations in the non- diabetics group for sEPCR (r=-0.449 p.adj=0.0417) with renal function as measured with MDRD. C) Correlations for the total population for Factor VIII with age (r=0.419, p. adj< 0.001), CRP with the subjects weight (r=0.352, p.adj< 0.01), and with BMI (r=0.51, p. adj< 0.00001).
Total population correlations
Treating the two groups as a single population other correlations became evident, most important shown in (Figure 1C). Factor VIII is seen to be strongly correlated with age (r=0.419, p. adj< 0.001). Also hsCRP is positively correlated with the subjects weight (r=0.352, p. adj< 0.01), more so if the BMI is considered (r=0.51, p. adj < 0.00001). Also evident, is the effect that thrombomodulin has to the renal function in the whole population, as it has a relative strong negative correlation with MDRD measurements (r=-0.510, p. adj< 0.00001) and a strong positive correlation (r=0.640, p. adj < 0.000000001) with creatinine. Similarly a negative correlation exists with homocysteine and MDRD (r=-0.410, p. adj< 0.001) coupled with a very strong positive correlation with creatinine r=0.500, p. adj< 0.00001). Factor VIII, on the other hand, is only negatively correlated with MDRD (r=-0.322, p. adj< 0.01). Fibrinogen also shows a negative correlation, albeit weaker, (r=0.380 p. adj< 0.01) with INR.
Very little is known for indicators such as thrombomodulin and sEPCR about their potential role as diagnostic markers in type 2 diabetes, to date there are few studies that have been published and for smaller numbers of patients. [10,11,14,15] The present study evaluated thrombomodulin [14,15] and sEPCR, amongst other well established indicators of thrombosis and endothelial inflammation, namely,  factor VIII,  (PAI 1), (VWF), [18-20] fibrinogen, d - dimers, hsCRP  and homocysteine  in a subset of Greek subjects with and without T2 Diabetdes, of similar age, similar distribution in terms of gender and nearly identical anthropometrically. A total number of 47 variables including biomarkers together with indicators for metabolic and clinical history profiles, as well as detailed anthropometric profiles and traditional risk factors, were evaluated.
The biomarkers associated with the onset and progression of T2 diabetes, DPP4, Insulin, use of Sulfonylurea, high HBA1c and glycose levels, were clearly statistically differentiated in the two groups, while no other biomarkers including thrombomodulin and sEPCR were found to be different.
Interestingly, high values of thrombomodulin and homocysteine, in the diabetic patients group, were correlated with a rise in creatinine  and thus could act as markers for renal function in T2 diabetes. Furthermore sEPCR was shown to have a relative strong negative correlation with renal function status as measured with MDRD in the non-diabetics group, indicating its value as another potential marker for renal function which is in agreement with the latest international findings .
The strengths of the current study include the complete concordance between the two groups in age, anthropometric elements, smoking habits and relevant clinical history profiles as well as the extensive number of factors tested, and the detailed and strict statistical analysis of the data. The main limitation of the study is the relative small number of subjects under investigation.
In conclusion the presence of T2 diabetes in conjunction with age, clearly correlates with problems in renal function, with thrombomodulin and homocysteine serving as indicators for renal damage in diabetics but not in healthy individuals as it has been previously extensively described . sEPCR on the other hand could be a potential generic indicator for renal damage in agreement with very recent research. Thrombomodulin and sEPCR as prothombotic agents, did not show any indication that they can be utilised as markers for the prevention and/or treatment of thrombotic complications in diabetic patients a conclusion that clearly a larger scale study could strengthen.